Board of Directors

Mark L. Baum is the founder, Chairman of the Board, and CEO of Harrow. For the 2014-2017 periods, Harrow (formerly Imprimis Pharmaceuticals) was named by Deloitte’s Technology Fast 500™ as one of the fastest growing companies in North America. Mr. Baum is also a founder of Eton Pharmaceuticals (NASDAQ: ETON) and Melt Pharmaceuticals, as well as a founder and board member of Surface Ophthalmics and Visionology. From 2014-2017, Mr. Baum was a senior advisor to VC-backed Curology.com. Prior to Harrow, as the founder of TBLF, LLC, a private investment fund manager, Mr. Baum made more than 200 investments into more than 40 private and public companies. In 1999, Mr. Baum founded YesRx, an HIV-focused pharmacy business. Mr. Baum’s advocacy for drug pricing and patient/physician accessibility issues has been featured in Op-Ed contributions for the Wall Street Journal and through appearances on CBS, CNN, MSNBC, Fox Business, Bloomberg and Al Jazeera. Mr. Baum was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region. Mr. Baum is a graduate, cum laude, of The University of Texas at Arlington and a 1997 graduate of California Western School of Law.

Adrienne L. Graves, Ph.D. has served as a director of the company since January of 2024. She previously served as President and Chief Executive Officer of Santen Inc., the United States subsidiary of a publicly traded Japanese pharmaceutical company, from 2002 to 2010 and as Senior Vice President of Worldwide Clinical Development (U.S., Europe, and Japan) from 1995 to 2002. Dr. Graves has served as a member of the boards of directors of Ocular Therapeutix, Inc., a biopharmaceutical company, since July 2023; Nicox S.A., a French ophthalmology company, since 2014, and Surface Ophthalmics, Inc., since 2018, a development stage ophthalmology pharmaceutical company. Previously, Dr. Graves served as a member of the board of directors of IVERIC bio, Inc., a biopharmaceutical company, from late 2018 to 2021 and as the chairman of IVERIC’s board from 2021 to 2023; Greenbrook TMS Inc., a Canadian neurology and medical device company, since 2018 to 2023; Oxurion NV, a Belgian biopharmaceutical company, from 2018 until 2023; Akorn Inc., a pharmaceutical company, from 2012 until late 2018; and TearLab Corporation (now Trukera Medical), a biopharmaceutical company, from 2005 until early 2018. Dr. Graves received a B.A. in psychology from Brown University and a Ph.D. in psychobiology from the University of Michigan and completed a postdoctoral fellowship in visual neuroscience at the University of Paris. Dr. Graves brings to the Board remarkable leadership skills, pharmaceutical development, and operational expertise across the pharmaceutical industry, including having brought multiple ophthalmic products through development to approval and commercialization as well as being responsible for numerous successful acquisitions and partnerships.

Marty Makary, M.D., M.P.H., has served as a director of the company since March of 2022. Dr. Makary is a healthcare expert and is Chief of Islet Transplant Surgery at The Johns Hopkins Hospital, where he has been employed since 2002. Dr. Makary is a frequent public policy expert in the media and a leading voice for physicians, writing for The Wall Street Journal. He is the author of two New York Times bestselling books on healthcare and has published over 250 scientific peer-reviewed articles, including articles on organizational culture, surgical innovation, vulnerable populations, and the re-design of healthcare delivery. Dr. Makary has served in leadership at the World Health Organization and has been elected to the National Academy of Medicine. Dr. Makary has been a visiting professor at over 25 medical schools and is the recipient of the Nobility in Science Award from the National Pancreas Foundation. Dr. Makary speaks frequently on the future of healthcare and what it means for everyday Americans, business leaders, and healthcare professionals. His current research focuses on the appropriateness of medical care and the impact of the healthcare cost crisis on low-income populations. He has a B.S. degree from Bucknell University, an M.D. degree from Thomas Jefferson University, and a Master of Public Health (M.P.H.) degree, with a concentration in Health Policy, from Harvard University. Dr. Makary brings to the board extensive experience as a surgeon, corporate advisor, and policy thought leader.

Lauren P. Silvernail has served as a director of the company since January of 2024. From 2018 to 2022, she was Chief Financial Officer and Executive Vice President, Corporate Development of Evolus, Inc., an aesthetic medicines company. Prior to that time, Mrs. Silvernail served as the Chief Financial Officer and Chief Business Officer of Revance Therapeutics, Inc., a development stage aesthetic medicine company, from late 2015 to 2018 and as Chief Financial Officer and Executive Vice President, Corporate Development from 2013 to 2015. From 2003 to 2012, Mrs. Silvernail was Chief Financial Officer and Vice President of Corporate Development at ISTA Pharmaceuticals, Inc., a commercial pharmaceutical company that was acquired by Bausch and Lomb. From 1995 to 2003, Mrs. Silvernail served in various operating and corporate development positions with Allergan, a pharmaceutical company, including Vice President, Business Development. Prior to joining Allergan, Mrs. Silvernail worked at Glenwood Ventures, an investment firm, as a General Partner. She currently serves on the board of directors and as chair of the audit committee at Harpoon Therapeutics, Inc., an immuno-oncology company that was recently acquired by Merck. In addition, she serves on the board of directors, as a member of the audit and compensation committees and as the chair of the corporate governance committee of Nicox S.A. Mrs. Silvernail holds a B.A. in Biophysics from the University of California, Berkeley and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles. Mrs. Silvernail brings to the Board a successful track record in operational, financial, and business development within the life sciences industry.

Teresa F. Sparks has served as a director of the company since March of 2020. She recently served as CFO and Executive Vice President of Envision Healthcare, a leading provider of physician-led services and post-acute care services in addition to ambulatory surgery services. Previously, she was the interim CFO at Brookdale Senior Living, the CFO at Surgery Partners and its predecessor company, Symbion. Ms. Sparks began her career with Deloitte in Nashville, Tennessee, and healthcare was her primary area of focus. She brings extensive public corporate leadership in addition to private equity experience, having led two initial public offerings, a leveraged buy-out, and multiple mergers and acquisitions. Her public company experience incorporates strategy development, risk assessment, investor relations, and corporate governance. She has served as the chairperson for the Nashville Health Care Council’s Leadership Health Care (LHC) program and served on the Board of Trustees at Trevecca Nazarene University. Ms. Sparks completed the requirements to be a Certified Public Accountant (inactive) in the State of Tennessee and holds a Bachelor of Science in Business Administration and Accounting from Trevecca Nazarene University, graduating with Summa Cum Laude honors.

Perry J. Sternberg has served as a director of the company since March of 2022. He has served as President and Chief Executive Officer of Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, since 2019. Prior to joining Corium, he served from 2013 to 2019 as Executive Vice President and Head of U.S. Commercial for Shire Plc’s ophthalmology business unit as well as six other Shire business units, which, during his tenure, in the aggregate, generated more than $8 billion in annual revenues. Mr. Sternberg also served as Chief Commercial Officer and Global Head of Shire’s CNS Business. Mr. Sternberg previously served as Vice President and General Manager, U.S. and Canada Pharmaceuticals at Bausch + Lomb, as well as various leadership roles at Novartis Ophthalmics, Novartis Pharmaceuticals and Merck & Co., Inc. He received a B.S. degree in Animal Bioscience from Penn State University in 1990. Mr. Sternberg brings to the board over 25 years of experience in biotechnology and pharmaceuticals, having had direct responsibility for the launch and commercialization of more than 20 products across a wide range of therapeutic areas in diverse markets, including ophthalmic pharmaceuticals.